Latest Press Releases
Statement on COVID-19
As we continue to monitor COVID-19 developments, at Neurocrine Biosciences we are committed to the safety, health and well-being of our patients, customers and employees. To healthcare providers and their patients with tardive dyskinesia or Parkinson’s disease, we do not anticipate any disruption in our ability to supply INGREZZA® (valbenazine) or ONGENTYS® (opicapone). Be assured, we remain focused on our mission to discover, develop and deliver important medicines to treat patients with neurological, endocrine, and psychiatric disorders.